epigenetics Archives

News and Trends 21 Jul 2017

Roche Abandons Spanish Cancer Epigenetics Drug

Roche has decided to terminate its license agreement with Spanish biotech Oryzon Genomics after rearranging its portfolio priorities. Oryzon Genomics, a biotech based in Barcelona working on epigenetics, was notified yesterday by Roche about the discontinuation of their deal concerning the biotech’s lead candidate, ORY-1001. Roche announced the decision was not based on clinical data, […]

July 21, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Interview 23 Mar 2017

Meet the CEO of this Intrepid Spanish Biotech exploring Epigenetics

Located right here in Barcelona, Oryzon is one of the world’s few epigenetics biotechs. I sat down with CEO Carlos Buesa to talk about its approach. Since its foundation in 2000, Oryzon has gone on to become the leader in epigenetic medicine and focuses on oncology. Most recently, the company announced the success of its lead […]

March 23, 2017 - 2 minutesmins - By Evelyn Warner

Screenshot 2016 11 22 at 1.33.19 PM e1479818165882

News and Trends 25 Nov 2016

Structural Biology meets Drug Discovery in this Cool Company

After an amazing day in Paris for Labiotech Refresh, we head back to Germany to meet Proteros. The company is working non-stop to provide drug candidates against some of the hottest targets in biotech. City: Munich, Germany Founded: 1999 Employees: 80+ Financial data: The company just announced a €157M ($167M) deal with MSD Mission: Proteros’ expertise in structural biology […]

November 25, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 28 Sep 2016

Little Biotechs manoeuvre to outfox Big Pharma in Immuno-Oncology

Giants like BMS and GSK have been throwing all the money they can at developing immuno-oncological treatments. In twin deals, four smaller companies are forging new paths to cure cancer with the human immune response. A pair of agreements among immuno-oncology biotechs have been made in attempts to outflank big pharma competition. In Scandinavia, Orion will fund […]

September 28, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 31 Aug 2016

No Tumour, No Cancer Cure: New Epigenetic Test can pinpoint Elusive Ones

Not all tumours are detectable, which makes them particularly deadly. Researchers at the University of Barcelona have developed an epigenetic test to find them, the first of its kind to diagnose tumour sources. Cancer starts with a tumour, which grows and eventually sheds cells. These cells lodge in other tissues in the body and grow […]

August 31, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 22 Jul 2016

Oryzon develops Epigenetic Therapies against Cancer and Alzheimer’s

This week we’re exchanging a very warm and welcoming country for another. We are heading to Barcelona, the wonderful capital of Catalunya in Spain, to visit Oryzon, our Biotech of The Week and maybe (just maybe) have a little swim in the Barceloneta beach. City: Barcelona (Spain) Founded: 2000 Employees: 35 Financial Data: €81.50M Market Cap (Bolsa de […]

July 22, 2016 - 2 minutesmins - By Joachim Eeckhout

deskgen desktop genetics biotech labiotech refresh crispr

News and Trends 5 Jul 2016

“CRISPR is highly fragmented, with too many approaches. We bring it all together”

The problem with CRISPR, is that not many people are actually experts in the field, and there are only a select few who worked on it pre-2013. So how did this UK Startup make a big name for itself in field of the ‘Biotech Breakthrough of the Century’? Desktop Genetics is a startup founded in 2012 by three […]

July 5, 2016 - 4 minutesmins - By Dani Bancroft

astrazeneca asthma copd epigenetic targets

News and Trends 21 Jun 2016

UK Partnership is looking for new Epigenetic targets in Respiratory Disease

AstraZeneca and MRC Technology are launching an initiative to find new epigenetic targets in respiratory disease. By picking promising academic research, the two parties expect to lock in new drugs for diseases like asthma. After partnering up with genomics elite for a new biobank, AstraZeneca is again preparing to tap into collaborations with academia. This […]

June 21, 2016 - 2 minutesmins - By Denise Neves Gameiro

wheat meiogenix spix epigenetics cambridge bbrsc

News and Trends 28 Apr 2016

French Biotech and Cambridge to improve Food Security with UK Grant

Meiogenix and the University of Cambridge will get fresh money to investigate how epigenomics impacts crop diversity – and how it can be engineered for better yields of wheat. Based in Paris, Meiogenix is developing breeding technologies – which already caught the eye of Bayer Crop Science. One of its platforms is SpiX, which increases the […]

April 28, 2016 - 2 minutesmins - By Denise Neves Gameiro

cambridge epigenix true methyl oxsb seq epigenome sequencing 5mc 5hmc gv sequoia geoff smith

News and Trends 14 Mar 2016

British Startup Raises Millions to Become the Illumina for Epigenetics

Cambridge Epigenetix (UK) wants to unlock the power of the Epigenome and become what Illumina is for NGS. And now, it has gotten the €18.9M and a new CEO needed to achieve this. Cambrige Epigenetix is a Biotech developing epigenetic tools, and was initially founded by Cambridge Enterprise (an incubator of the University of Cambridge) and […]

March 14, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 24 Feb 2016

German Biotech wins FDA Approval for New Liver Cancer Trial

4SC, in Germany, has the FDA’s green light to conduct efficacy trials in the US with a candidate drug against hepatocellular carcinoma. Munich-based 4SC’s lead candidate, resminostat, is a small-molecule being tested in several trials for some of the deadliest cancers. These include liver – which is also known as hepatocellular carcinoma (HCC). Resminostat is an inhibitor of histone […]

February 24, 2016 - 3 minutesmins - By Denise Neves Gameiro

desktop genetics gene ngs illumina epigenetics

News and Trends 23 Feb 2016

UK Start-Up Gets €380k to Understand Cancer with CRISPR

Desktop Genetics, a small bioinformatics start-up out of London, has won a substantial grant to understand why some cancer cells just won’t quit. To do this, it relies on CRISPR, their expertise with genetic data, and research from Imperial College London. Desktop Genetics has already proven that it can move some money, with a €1.87 […]

February 23, 2016 - 3 minutesmins - By Denise Neves Gameiro

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us